It was believed that pharmacists recognised this and consequently their demands for development had increased. In terms of ‘responding to changes in the profession’ pharmacist development was seen as an investment choice with business benefits balanced against costs. In-house training was considered to facilitate greater control over pharmacist development than more costly externally provided courses, for which changes in practice were not always evident. Support Bortezomib mouse for external courses such as postgraduate diplomas tended to be offered to pharmacists that were performing well and had demonstrated commitment to the company. Completion of these courses was
thought to result in some pharmacists leaving the company to pursue other roles and the unclear career pathway in community pharmacy was believed to contribute to this. DZNeP Results are based on the opinions of four individuals and whilst they may be representative of SLDMs at other LMCPs they cannot be generalised further. Participants believed that training and development
was required beyond that delivered up to registration to enable community pharmacists to perform effectively, thus supporting the current drive to change undergraduate and early career development. Externally provided postgraduate education has not been widely supported as a means of facilitating this because of concerns about costs, with little evidence available to demonstrate a positive return on investment. Instead the focus has been on in-house training which allows closer control of pharmacists’ development and the costs involved. Whilst completion of a postgraduate qualification was thought to result in people changing their career companies are using them as a reward when there may be a greater gain made by investing in those underperforming and less committed. If external postgraduate
education is to be more widely supported providers Methamphetamine should ensure courses are designed to deliver outcomes which justify the costs involved. 1. Howe H, Wilson K. Review of post-registration career development: Next steps. Report to Medical Education England Board 2012. 2. Seston L, Hassell K. Pharmacy Workforce Census 2008: Main findings. London, 2009. Bridget Coleman1, Apirati Yangphaibul2, Maja Begovic1 1Whittington Health, London, UK, 2UCL, School of Pharmacy, London, UK A pilot study assessed the contribution made by a non-medical prescribing pharmacist to a musculoskeletal (MSK) chronic pain clinic in primary care The clinic pharmacist performed a mean of 2.5 actions per patient (n = 32) to optimise therapy, reduce adverse effects and enhance adherence to medicines Members of the chronic pain team indicated that the pharmacist added value to patient care This new pharmacist role is being continued, developed and further evaluated.